Indoleamine 2,3 dioxygenase contributes to transferable tolerance in rat red blood cell inducible model of experimental autoimmune haemolytic anaemia

L. N. Dahal, L. S. Hall, R. N. Barker, F. J. Ward

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Autoimmune haemolytic anaemia (AIHA) is caused by autoantibodies against RBC
surface antigens that render RBC susceptible to Fc-mediated phagocytosis and
complement mediated lysis. Experimental AIHA can be induced by injection of rat
RBC to naïve mouse but a lymphocyte-mediated regulatory mechanism eventually
suppresses the production of autoantibodies specific for mouse RBC. Critically, this
tolerogenic response can be transferred to naïve mouse by splenocytes from rat
RBC immunized mouse. Here we investigate whether Indoleamine 2,3 dioxygenase
(IDO) or the initiators of IDO cascade, particularly CTLA-4 receptor and its soluble
isoform contribute to this tolerogenic mechanism. Splenocytes from experimental
AIHA mice were adoptively transferred to naive mice under the cover of anti-CTLA-4,
anti-soluble CTLA-4 antibodies or IDO inhibitor 1-Methyl Tryptophan (1-MT).
Recipient mice were immunized with rat RBC and levels of antibody against self-
RBC and rat-RBC were monitored. Our results indicate that transfer of tolerance to
naïve recipients is dependent on IDO mediated immunosuppression as mice
receiving previously tolerized splenocytes under the cover of 1-MT were refractory to
tolerance and developed haemolytic disease upon further challenge with rat RBC.
Initiators of IDO activity, CTLA-4 or soluble CTLA-4 did not mediate this tolerogenic
process but on their blockade, boosted antigen-specific effector immune responses.
Original languageEnglish
Pages (from-to)58-66
Number of pages9
JournalClinical and Experimental Immunology
Volume173
Issue number1
Early online date6 Jan 2013
DOIs
Publication statusPublished - Jul 2013

Fingerprint

Indoleamine-Pyrrole 2,3,-Dioxygenase
Autoimmune Hemolytic Anemia
Theoretical Models
Erythrocytes
Autoantibodies
Antigens
Antibodies
Phagocytosis
Immunosuppression
Lymphocytes
Injections

Keywords

  • autoimmune-disease
  • indoleamine 2,3-dioxygenase
  • hemolytic anemia
  • 1-MT
  • autoimmune haemolytic anaemia
  • CTLA-4
  • IDO
  • tolerance

Cite this

Indoleamine 2,3 dioxygenase contributes to transferable tolerance in rat red blood cell inducible model of experimental autoimmune haemolytic anaemia. / Dahal, L. N.; Hall, L. S.; Barker, R. N.; Ward, F. J.

In: Clinical and Experimental Immunology, Vol. 173, No. 1, 07.2013, p. 58-66.

Research output: Contribution to journalArticle

@article{b3b78f3afd224d3cb7049e57337ed113,
title = "Indoleamine 2,3 dioxygenase contributes to transferable tolerance in rat red blood cell inducible model of experimental autoimmune haemolytic anaemia",
abstract = "Autoimmune haemolytic anaemia (AIHA) is caused by autoantibodies against RBC surface antigens that render RBC susceptible to Fc-mediated phagocytosis and complement mediated lysis. Experimental AIHA can be induced by injection of rat RBC to na{\"i}ve mouse but a lymphocyte-mediated regulatory mechanism eventually suppresses the production of autoantibodies specific for mouse RBC. Critically, this tolerogenic response can be transferred to na{\"i}ve mouse by splenocytes from rat RBC immunized mouse. Here we investigate whether Indoleamine 2,3 dioxygenase (IDO) or the initiators of IDO cascade, particularly CTLA-4 receptor and its soluble isoform contribute to this tolerogenic mechanism. Splenocytes from experimental AIHA mice were adoptively transferred to naive mice under the cover of anti-CTLA-4, anti-soluble CTLA-4 antibodies or IDO inhibitor 1-Methyl Tryptophan (1-MT). Recipient mice were immunized with rat RBC and levels of antibody against self- RBC and rat-RBC were monitored. Our results indicate that transfer of tolerance to na{\"i}ve recipients is dependent on IDO mediated immunosuppression as mice receiving previously tolerized splenocytes under the cover of 1-MT were refractory to tolerance and developed haemolytic disease upon further challenge with rat RBC. Initiators of IDO activity, CTLA-4 or soluble CTLA-4 did not mediate this tolerogenic process but on their blockade, boosted antigen-specific effector immune responses.",
keywords = "autoimmune-disease, indoleamine 2,3-dioxygenase, hemolytic anemia, 1-MT, autoimmune haemolytic anaemia, CTLA-4, IDO, tolerance",
author = "Dahal, {L. N.} and Hall, {L. S.} and Barker, {R. N.} and Ward, {F. J.}",
year = "2013",
month = "7",
doi = "10.1111/cei.12091",
language = "English",
volume = "173",
pages = "58--66",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Indoleamine 2,3 dioxygenase contributes to transferable tolerance in rat red blood cell inducible model of experimental autoimmune haemolytic anaemia

AU - Dahal, L. N.

AU - Hall, L. S.

AU - Barker, R. N.

AU - Ward, F. J.

PY - 2013/7

Y1 - 2013/7

N2 - Autoimmune haemolytic anaemia (AIHA) is caused by autoantibodies against RBC surface antigens that render RBC susceptible to Fc-mediated phagocytosis and complement mediated lysis. Experimental AIHA can be induced by injection of rat RBC to naïve mouse but a lymphocyte-mediated regulatory mechanism eventually suppresses the production of autoantibodies specific for mouse RBC. Critically, this tolerogenic response can be transferred to naïve mouse by splenocytes from rat RBC immunized mouse. Here we investigate whether Indoleamine 2,3 dioxygenase (IDO) or the initiators of IDO cascade, particularly CTLA-4 receptor and its soluble isoform contribute to this tolerogenic mechanism. Splenocytes from experimental AIHA mice were adoptively transferred to naive mice under the cover of anti-CTLA-4, anti-soluble CTLA-4 antibodies or IDO inhibitor 1-Methyl Tryptophan (1-MT). Recipient mice were immunized with rat RBC and levels of antibody against self- RBC and rat-RBC were monitored. Our results indicate that transfer of tolerance to naïve recipients is dependent on IDO mediated immunosuppression as mice receiving previously tolerized splenocytes under the cover of 1-MT were refractory to tolerance and developed haemolytic disease upon further challenge with rat RBC. Initiators of IDO activity, CTLA-4 or soluble CTLA-4 did not mediate this tolerogenic process but on their blockade, boosted antigen-specific effector immune responses.

AB - Autoimmune haemolytic anaemia (AIHA) is caused by autoantibodies against RBC surface antigens that render RBC susceptible to Fc-mediated phagocytosis and complement mediated lysis. Experimental AIHA can be induced by injection of rat RBC to naïve mouse but a lymphocyte-mediated regulatory mechanism eventually suppresses the production of autoantibodies specific for mouse RBC. Critically, this tolerogenic response can be transferred to naïve mouse by splenocytes from rat RBC immunized mouse. Here we investigate whether Indoleamine 2,3 dioxygenase (IDO) or the initiators of IDO cascade, particularly CTLA-4 receptor and its soluble isoform contribute to this tolerogenic mechanism. Splenocytes from experimental AIHA mice were adoptively transferred to naive mice under the cover of anti-CTLA-4, anti-soluble CTLA-4 antibodies or IDO inhibitor 1-Methyl Tryptophan (1-MT). Recipient mice were immunized with rat RBC and levels of antibody against self- RBC and rat-RBC were monitored. Our results indicate that transfer of tolerance to naïve recipients is dependent on IDO mediated immunosuppression as mice receiving previously tolerized splenocytes under the cover of 1-MT were refractory to tolerance and developed haemolytic disease upon further challenge with rat RBC. Initiators of IDO activity, CTLA-4 or soluble CTLA-4 did not mediate this tolerogenic process but on their blockade, boosted antigen-specific effector immune responses.

KW - autoimmune-disease

KW - indoleamine 2,3-dioxygenase

KW - hemolytic anemia

KW - 1-MT

KW - autoimmune haemolytic anaemia

KW - CTLA-4

KW - IDO

KW - tolerance

U2 - 10.1111/cei.12091

DO - 10.1111/cei.12091

M3 - Article

VL - 173

SP - 58

EP - 66

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 1

ER -